Double-blind, placebo-controlled study of a once-a-day, sustained- release preparation of alprazolam for the treatment of panic disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The goals of this study were to assess the antipanic efficacy of a new, sustained-release formulation of alprazolam and to assess the safety and tolerability of once-a-day administration of 1-10 mg of sustained-release alprazolam. METHOD: One hundred ninety-four patients with diagnosis of agoraphobia with panic attacks or panic disorder with limited phobic avoidance underwent a 1-week placebo washout before being randomly assigned to groups receiving 8 weeks of double-blind treatment with either sustained-release alprazolam or placebo. RESULTS: There was a significant treatment effect favoring sustained-release alprazolam (highest mean dose = 4.7 mg/day) across almost all measures of anxiety, panic, and phobic avoidance, despite a significantly higher dropout rate in patients receiving placebo. Eighty-five percent of the patients treated with sustained-release alprazolam, compared with 61% of the patients given placebo, reported complete blockade of panic attacks by the end of 6 weeks of treatment. Sedation was the most commonly reported adverse effect. Discontinuation of sustained-release alprazolam was associated with moderate but transient levels of distress in 48% of the patients; discontinuation of placebo led to distress in only 10% of the patients. Nonetheless, there was no difference in the proportion of patients who were able to remain off the study drug for at least 2 weeks. CONCLUSIONS: These results suggest that sustained-release alprazolam is highly effective in the acute treatment of panic disorder at doses comparable to those in the originally marketed compressed tablet of alprazolam. The medication was well tolerated but showed rebound effects during a rapid drug taper after 6 weeks of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Self-citationChouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
Self-citation
Cited by
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
Sertraline treatment of panic disorder: results of a long-term study
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2001.00263.x · Cited by 79
Potential effectiveness and safety of olanzapine in refractory panic disorder
Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005) · Depression and Anxiety · doi:10.1002/da.20050 · Cited by 58
The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder
Susman, J., & Klee, B. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0101 · Cited by 39
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1993-08-01
- Volume
- 150
- Issue
- 8
- Pages
- 1210-1215
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2418642998
- Cited by
- 45
- References
- 4
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-blind, placebo-controlled study of a once-a-day, sustained- release preparation of alprazolam for the treatment of panic disorder. https://app.cochat.ai/papers/10.1176/ajp.150.8.1210
- The paper
- Double-blind, placebo-controlled study of a once-a-day, sustained- release preparation of alprazolam for the treatment of panic disorder. (1993). American Journal of Psychiatry. https://doi.org/10.1176/ajp.150.8.1210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.